Scientific Director - Publications
The Lockwood Group, LLCSalary not specified
- Full Time
- Senior (5 to 8 years)
Not SpecifiedCompensation
Senior (5 to 8 years)Experience Level
Full TimeJob Type
UnknownVisa
Biopharmaceuticals, Pharmaceuticals, Life SciencesIndustries
Requirements
Candidates should possess an undergraduate college degree preferred, along with 5+ years of experience in the pharmaceutical or healthcare industry with a focus on scientific publications. They should demonstrate proven project management skills and a track record of executing projects in a matrix environment, working across multiple functional areas. A strong understanding of Good Publication Practices (GPP4), ICMJE, CONSORT, Sunshine Act, and other relevant publications industry standards is required, alongside demonstrated proficiency in project management and organization.
Responsibilities
The Senior Manager, Publications Project Management will manage the publications review process for manuscripts from various departments, liaise with technical support for PubSTRAT MAX, generate reports to monitor timelines, and maintain publication resources. They will provide support for new publications by circulating proposals, reaching out to authors, and following up on reviews. Additionally, they will support encore congress abstracts/presentations, assist with developing publications-related materials, streamline the publication process, and perform other tasks as needed and specified by the manager.
Skills
Publication Management
Project Management
Stakeholder Coordination
System Management
Reporting and Tracking
Publication Review Process
Regulatory Compliance
Process Optimization
Axsome Therapeutics Inc
Develops therapies for CNS disorders
About Axsome Therapeutics Inc
Axsome Therapeutics develops therapies for central nervous system (CNS) disorders, focusing on conditions like major depressive disorder, treatment-resistant depression, and Alzheimer's agitation. Their main product, AXS-05, is an oral medication that works by blocking NMDA receptors in the brain, which helps regulate mood. This drug has shown positive results in clinical trials and has received special FDA status to speed up its approval process. Unlike many competitors, Axsome emphasizes addressing unmet medical needs in CNS disorders and aims to improve patient outcomes through rigorous research and development. The company's goal is to bring effective treatments to market, enhancing the quality of life for patients suffering from these conditions.
New York City, New YorkHeadquarters
2012Year Founded
$430.7MTotal Funding
IPOCompany Stage
Biotechnology, HealthcareIndustries
201-500Employees